Ainos to implement 5-for-1 stock consolidation

Ainos (AIMD) will implement a consolidation of its common stock, effective at the opening of trading on June 30. This strategic action positions Ainos to attract broader institutional interest as it enters a commercial execution phase in the second half of 2025 and supports the Company’s continued Nasdaq listing. This action aligns with the Company’s 2025 execution roadmap, as Ainos advances pilot programs of its AI-powered scent digitization platform, AI Nose, and clinical development of VELDONA, its low-dose oral interferon, across both human and veterinary indications. Following the stock consolidation, every five shares of issued and outstanding common stock will automatically be combined and convert into one share. The stock consolidation reduces the number of shares of the Company’s outstanding common stock. No fractional shares will be issued, and holders of fractional shares will be paid out in cash for the fractional portion. The Company’s common stock will continue trading under the same Nasdaq ticker symbol, with a new CUSIP number, 00902F402.